Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBP-812 Gene Therapy for Canavan Disease
NCT04998396Phase 2Recruiting
- Sponsor
- Aspa Therapeutics
- Start
- Sep 2021
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Gene Silencing, RNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BBP-812 in Canavan disease, sponsored by Aspa Therapeutics. Started Sep 2021; status: recruiting.
02
Drugs
BBP-812
03
Conditions
Canavan disease
Beyond the preview
Go deeper on NCT04998396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998396.